Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response

Background: Endothelial dysfunction is central to PAH. In this study, we simultaneously analysed circulating levels of endothelial microvesicles (EMVs) and progenitor cells (PCs) in PAH and in controls, as biomarkers of pulmonary endothelial integrity and evaluated differences among PAH subtypes and...

Descripción completa

Detalles Bibliográficos
Autores: Tura-Ceide, Olga, Blanco, Isabel, Garcia-Lucio, Jéssica, del Pozo, Roberto, García, Agustín Roberto, Ferrer, Elisabet, Crespo, Isabel, Rodríguez Chiaradia, Diego Agustín, Simeon-Aznar, Carmen Pilar, López-Meseguer, Manuel, Martín-Ontiyuelo, Clara, Peinado, Victor I., Barberà, Joan Albert
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/53251
Acceso en línea:http://hdl.handle.net/10230/53251
http://dx.doi.org/10.3390/cells10071688
Access Level:acceso abierto
Palabra clave:PAH-specific treatment
Biomarkers
Endothelial dysfunction
Endothelial extracellular vesicles
Progenitor cells
Pulmonary arterial hypertension
id ES_f5e9da478d5fa9ba1dc6af0722fdfabd
oai_identifier_str oai:recercat.cat:10230/53251
network_acronym_str ES
network_name_str España
repository_id_str
spelling Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic responseTura-Ceide, OlgaBlanco, IsabelGarcia-Lucio, Jéssicadel Pozo, RobertoGarcía, Agustín RobertoFerrer, ElisabetCrespo, IsabelRodríguez Chiaradia, Diego AgustínSimeon-Aznar, Carmen PilarLópez-Meseguer, ManuelMartín-Ontiyuelo, ClaraPeinado, Victor I.Barberà, Joan AlbertPAH-specific treatmentBiomarkersEndothelial dysfunctionEndothelial extracellular vesiclesProgenitor cellsPulmonary arterial hypertensionBackground: Endothelial dysfunction is central to PAH. In this study, we simultaneously analysed circulating levels of endothelial microvesicles (EMVs) and progenitor cells (PCs) in PAH and in controls, as biomarkers of pulmonary endothelial integrity and evaluated differences among PAH subtypes and as a response to treatment. Methods: Forty-seven controls and 144 patients with PAH (52 idiopathic, 9 heritable, 31 associated with systemic sclerosis, 15 associated with other connective tissue diseases, 20 associated with HIV and 17 associated with portal hypertension) were evaluated. Forty-four patients with scleroderma and 22 with HIV infection, but without PAH, were also studied. Circulating levels of EMVs, total (CD31+CD42b-) and activated (CD31+CD42b-CD62E+), as well as circulating PCs (CD34+CD133+CD45low) were measured by flow cytometry and the EMVs/PCs ratio was computed. In treatment-naïve patients, measurements were repeated after 3 months of PAH therapy. Results: Patients with PAH showed higher numbers of EMVs and a lower percentage of PCs, compared with healthy controls. The EMV/PC ratio was increased in PAH patients, and in patients with SSc or HIV without PAH. After starting PAH therapy, individual changes in EMVs and PCs were variable, without significant differences being observed as a group. Conclusion: PAH patients present disturbed vascular homeostasis, reflected in changes in circulating EMV and PC levels, which are not restored with PAH targeted therapy. Combined measurement of circulating EMVs and PCs could be foreseen as a potential biomarker of endothelial dysfunction in PAH.MDPI202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/53251http://dx.doi.org/10.3390/cells10071688reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCopyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/532512026-05-29T05:05:01Z
dc.title.none.fl_str_mv Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
title Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
spellingShingle Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
Tura-Ceide, Olga
PAH-specific treatment
Biomarkers
Endothelial dysfunction
Endothelial extracellular vesicles
Progenitor cells
Pulmonary arterial hypertension
title_short Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
title_full Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
title_fullStr Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
title_full_unstemmed Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
title_sort Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
dc.creator.none.fl_str_mv Tura-Ceide, Olga
Blanco, Isabel
Garcia-Lucio, Jéssica
del Pozo, Roberto
García, Agustín Roberto
Ferrer, Elisabet
Crespo, Isabel
Rodríguez Chiaradia, Diego Agustín
Simeon-Aznar, Carmen Pilar
López-Meseguer, Manuel
Martín-Ontiyuelo, Clara
Peinado, Victor I.
Barberà, Joan Albert
author Tura-Ceide, Olga
author_facet Tura-Ceide, Olga
Blanco, Isabel
Garcia-Lucio, Jéssica
del Pozo, Roberto
García, Agustín Roberto
Ferrer, Elisabet
Crespo, Isabel
Rodríguez Chiaradia, Diego Agustín
Simeon-Aznar, Carmen Pilar
López-Meseguer, Manuel
Martín-Ontiyuelo, Clara
Peinado, Victor I.
Barberà, Joan Albert
author_role author
author2 Blanco, Isabel
Garcia-Lucio, Jéssica
del Pozo, Roberto
García, Agustín Roberto
Ferrer, Elisabet
Crespo, Isabel
Rodríguez Chiaradia, Diego Agustín
Simeon-Aznar, Carmen Pilar
López-Meseguer, Manuel
Martín-Ontiyuelo, Clara
Peinado, Victor I.
Barberà, Joan Albert
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv PAH-specific treatment
Biomarkers
Endothelial dysfunction
Endothelial extracellular vesicles
Progenitor cells
Pulmonary arterial hypertension
topic PAH-specific treatment
Biomarkers
Endothelial dysfunction
Endothelial extracellular vesicles
Progenitor cells
Pulmonary arterial hypertension
description Background: Endothelial dysfunction is central to PAH. In this study, we simultaneously analysed circulating levels of endothelial microvesicles (EMVs) and progenitor cells (PCs) in PAH and in controls, as biomarkers of pulmonary endothelial integrity and evaluated differences among PAH subtypes and as a response to treatment. Methods: Forty-seven controls and 144 patients with PAH (52 idiopathic, 9 heritable, 31 associated with systemic sclerosis, 15 associated with other connective tissue diseases, 20 associated with HIV and 17 associated with portal hypertension) were evaluated. Forty-four patients with scleroderma and 22 with HIV infection, but without PAH, were also studied. Circulating levels of EMVs, total (CD31+CD42b-) and activated (CD31+CD42b-CD62E+), as well as circulating PCs (CD34+CD133+CD45low) were measured by flow cytometry and the EMVs/PCs ratio was computed. In treatment-naïve patients, measurements were repeated after 3 months of PAH therapy. Results: Patients with PAH showed higher numbers of EMVs and a lower percentage of PCs, compared with healthy controls. The EMV/PC ratio was increased in PAH patients, and in patients with SSc or HIV without PAH. After starting PAH therapy, individual changes in EMVs and PCs were variable, without significant differences being observed as a group. Conclusion: PAH patients present disturbed vascular homeostasis, reflected in changes in circulating EMV and PC levels, which are not restored with PAH targeted therapy. Combined measurement of circulating EMVs and PCs could be foreseen as a potential biomarker of endothelial dysfunction in PAH.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/53251
http://dx.doi.org/10.3390/cells10071688
url http://hdl.handle.net/10230/53251
http://dx.doi.org/10.3390/cells10071688
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424660194525184
score 15.81155

Similares en LA Referencia